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ABSTRACT
Background
Between 1995 and 2000, KwaZulu–Natal province, South Africa, experienced a marked
increase in Plasmodium falciparum malaria, fuelled by pyrethroid and sulfadoxine-pyrimeth-
amine resistance. In response, vector control was strengthened and artemether-lumefantrine
(AL) was deployed in the first Ministry of Health artemisinin-based combination treatment
policy in Africa. In South Africa, effective vector and parasite control had historically ensured
low-intensity malaria transmission. Malaria is diagnosed definitively and treatment is provided
free of charge in reasonably accessible public-sector health-care facilities.
Methods and Findings
We reviewed four years of malaria morbidity and mortality data at four sentinel health-care
facilities within KwaZulu–Natal’s malaria-endemic area. In the year following improved vector
control and implementation of AL treatment, malaria-related admissions and deaths both
declined by 89%, and outpatient visits decreased by 85% at the sentinel facilities. By 2003,
malaria-related outpatient cases and admissions had fallen by 99%, and malaria-related deaths
had decreased by 97%. There was a concomitant marked and sustained decline in notified
malaria throughout the province. No serious adverse events were associated causally with AL
treatment in an active sentinel pharmacovigilance survey. In a prospective study with 42 d
follow up, AL cured 97/98 (99%) and prevented gametocyte developing in all patients.
Consistent with the findings of focus group discussions, a household survey found self-
reported adherence to the six-dose AL regimen was 96%.
Conclusion
Together with concurrent strengthening of vector control measures, the antimalarial
treatment policy change to AL in KwaZulu–Natal contributed to a marked and sustained
decrease in malaria cases, admissions, and deaths, by greatly improving clinical and
parasitological cure rates and reducing gametocyte carriage.
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Malaria morbidity and mortality in Africa has risen,
principally because of increasing resistance to chloroquine
and sulfadoxine-pyrimethamine (SP) in Plasmodium falciparum
[1,2]. Highly successful malaria control in South Africa,
before the mid–1990s, had been achieved through high
coverage with effective indoor residual spraying (IRS) and
early access to effective antimalarial treatment. In KwaZulu–
Natal in 1988, SP ofﬁcially replaced chloroquine (CQ) as ﬁrst-
line treatment of uncomplicated malaria. In 1996, rapid
immunochromatographic card tests were implemented to
ensure deﬁnitive malaria diagnosis in all public-sector health-
care facilities. Between 1995 and 2000 there was a dramatic
increase in malaria morbidity and mortality in KwaZulu–
Natal (Figure 1). Reinvasion of the area by the highly
anthropophilic vector Anopheles funestus, which was resistant
to pyrethroids, and a rapid increase in SP resistance in P.
falciparum were considered the main contributors to this
epidemic [3–5].
To improve control of the A. funestus vector, an effective
insecticide, dichlorodiphenyltrichloroethane (DDT), was re-
introduced in March 2000 to replace failing pyrethroids for
IRS of traditional (mud, reed, or wood) homesteads. However,
western style structures, which constitute at least 40% of
homesteads in the study area, continued to be sprayed with
the pyrethroids because the residue left by DDT on painted
or cement-plastered surfaces is aesthetically unacceptable. By
2003, A. funestus s.s. was identiﬁed in only three sites in
northern KwaZulu–Natal [6], whereas A. arabiensis continues
to be found sporadically in window exit traps throughout
northern KwaZulu–Natal.
By 2000 the 42-d cure rate after antimalarial treatment
with SP had fallen to 11% [5]. In response to this drug-
resistant malaria epidemic, KwaZulu–Natal was the ﬁrst
Ministry of Health in Africa to implement an artemisinin-
based combination therapy (ACT) as ﬁrst-line treatment of
uncomplicated P. falciparum malaria. The decision to adopt an
ACT policy was inﬂuenced by the sustained high cure rates,
decreased malaria transmission, and decreased antimalarial
resistance that had been documented on the western border
of Thailand [7]. It was supported by a growing international
consensus that wide-scale systematic implementation of ACT
is one of few effective measures that could enable malaria-
endemic countries to achieve the ambitious goals set in Abuja
to ‘‘Roll Back Malaria,’’ particularly the halving of malaria
morbidity and mortality by 2010 [8]. Improved cure rates and
decreased gametocyte carriage had been conﬁrmed in recent
large randomised controlled clinical trials conducted across
Africa [9,10]. Decreased gametocyte carriage after AL treat-
ment has been shown to reduce post-treatment transmission
of P. falciparum to Anopheles mosquitoes [11].
Artemether-lumefantrine (AL; Coartem, Novartis, Kemp-
ton Park, South Africa) was the only ACT available in 2000
Figure 1. Number of Notified Malaria Cases in KwaZulu–Natal by Month (January 1993–December 2003)
The number of cases is given in relation to season (peak transmission from January to May, inclusive) and timing of significant malaria control
interventions: A indicates reintroduction of DDT for IRS of traditional structures in KwaZulu–Natal in March 2000; B indicates introduction of IRS in
southern Mozambique in October 2000; and C indicates implementation of AL as first-line treatment of uncomplicated falciparum malaria in KwaZulu–
Natal in January 2001.
DOI: 10.1371/journal.pmed.0020330.g001
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Effect of AL and IRS on Malaria Burdenwith sufﬁcient data to support fast-track registration by the
South African drug regulatory authority. High levels of
resistance in P. falciparum to CQ, SP, and amodiaquine in
KwaZulu–Natal precluded their use in artemisinin-based
combinations [5,12].
Although at least 14 African countries have recently
adopted an ACT malaria treatment policy and an increasing
number are in the process of changing to ACTs because of
high levels of resistance to CQ and SP (the traditional ﬁrst-
line antimalarials) [13], concern has been expressed that the
beneﬁts of ACT observed in Asia have not yet been proven in
Africa and may be inﬂuenced by coverage, adherence, quality,
affordability, and access issues [14–17]. International subsidy
of ACT costs has been widely recommended to address
affordability constraints, although supply and quality issues
currently remain substantial obstacles [18–20].
This study is a comprehensive evaluation of the ﬁrst
programme-wide implementation of ACT in Africa, describ-
ing changes in clinical and parasitological cure rates,
gametocyte carriage, community perspectives on malaria
treatment, and the impact of this ACT deployment and the
strengthening of vector control on the number of malaria
cases, admissions, and deaths. The factors considered to have
contributed to the observed changes in morbidity and
mortality are described.
Methods
Study Site
KwaZulu–Natal province, which has approximately 600,000
people living in malaria-risk areas, experienced the highest
intensity malaria transmission in South Africa before 2001.
Malaria risk and distribution is monitored through the
provincial malaria geographic information systems that
record all notiﬁed malaria cases, and provincial records are
collated nationally [21]. Malaria transmission in South Africa
has been restricted over the past four decades to the
northeastern border areas with Mozambique, Swaziland,
and Zimbabwe, primarily as a result of annual widespread
IRS with insecticides by the provincial malaria control
programmes, just prior to the malaria transmission season
[22] and early effective treatment. Historically, the main
mosquito vectors were the A. funestus group, which was
considered to have been eradicated by IRS, and A. arabiensis,
an efﬁcient vector that displays both indoor and outdoor
biting and resting behaviour, and thus is less readily
controlled by IRS [23]. Following the identiﬁcation of A.
funestus resistant to pyrethroids in 1999 [3], traditional
structures were sprayed with DDT (2 g/m
2) although a
pyrethroid (deltamethrin 0.02 g/m
2) had to be applied to
western-style structures.
Malaria transmission in KwaZulu–Natal is low (annual
entomological inoculation rate ,1; B. Sharp, unpublished
data) and seasonal (Figure 1) [22]. The four sentinel health-
care facilities studied, namely Ndumo clinic and Mosvold,
Manguzi, and Bethesda rural district hospitals, are all located
in Umkhanyakude district, which bears the heaviest malaria
burden in KwaZulu–Natal (Figure 2). P. falciparum accounts
for the majority (85%–100%) of infections.
South Africa has a decentralized health-care system.
Antimalarial resistance patterns vary geographically. Malaria
treatment policies have differed between provinces since
1988, when KwaZulu–Natal introduced SP to replace failing
CQ, nine years before SP was introduced in the two other
South African provinces with malaria transmission.
AL was implemented ofﬁcially as ﬁrst-line treatment of
uncomplicated malaria in KwaZulu–Natal’s public-health
sector during January 2001 [24]. Malaria treatment in South
Africa is administered on the basis of a P. falciparum–positive
malaria smear or rapid immunodiagnostic card test. These
tests are performed on all patients in whom malaria is
clinically suspected; diagnostic quality control is regularly
assessed by the Department of Health and the National
Health Laboratory Services. Malaria treatment is provided
free of charge in public-sector health-care facilities. AL was
implemented 6 mo after the high SP failure rates were
detected, and this delay consisted of a 3-mo policymaking
process and a further 3-mo implementation preparation
phase. AL was distributed to all public-sector ﬁxed clinics (n¼
50) and district hospitals (n ¼5) in Umkhanyakude district in
24-tablet individual patient blister packs, for administration
according to age–weight categories in a six-dose regimen over
3 d. Quinine remained the recommended treatment for
severe malaria and for uncomplicated malaria in pregnant
women and infants under 1 y of age. The implementation of
AL included face-to-face training of public-sector health-care
providers and distribution of speciﬁc malaria treatment
guidelines and wall charts, and was followed by systematic
withdrawal of SP.
Facility Review of Malaria Cases, Admissions, and Deaths
Malaria morbidity and mortality data were collected
retrospectively by reviewing hospital records provided by
the medical superintendents between 2000 and 2003 at the
sentinel clinic, Ndumo clinic, and the three sentinel hospitals,
namely Manguzi, Mosvold, and Bethesda hospitals that serve
Umkhanyakude district where the vast majority of malaria
cases occur in KwaZulu–Natal (Figure 2). Malaria cases were
deﬁned as patients with clinical features of malaria in whom
Plasmodium parasites were detected on malaria smear or rapid
diagnostic test. Those malaria cases requiring admission for
management of severe disease or that were considered a high-
risk group, including infants and pregnant women, were
classiﬁed as malaria-related hospital admissions. Malaria-
related deaths were patients in whom malaria was included as
a cause of death on the death certiﬁcate. Death-register data
included those deaths that occurred outside the hospitals but
were registered at a hospital for the purpose of issuing a
death certiﬁcate required for burial.
In Vivo Therapeutic Efficacy Study
Between January and June 2002, an open-label in vivo study
was conducted to determine the therapeutic efﬁcacy of a six-
dose regimen of AL administered over 3 d (total adult dose
480 mg artemether/2,880 mg lumefantrine; Coartem, Novar-
tis, Kempton Park, South Africa). Patients presenting
sequentially to Ndumo clinic with an axillary temperature
  37.5
8C or a history of fever, who were older than 12 mo,
weighed more than 10 kg, and lived close enough to the clinic
to allow reliable follow-up, were screened for P. falciparum
infection using a rapid immunochromatographic card test
for detecting histidine-rich protein-2 (Malaria PF/PV
ICTML02;SA Scientiﬁc Products, Midrand, South Africa). P.
falciparum infection was conﬁrmed by a positive Giemsa-
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all patients (or their guardians) with proven uncomplicated
falciparum malaria and a parasite density between 1,000 and
500,000 asexual parasites/ll blood. Patients who reported
receiving antimalarial treatment in the previous 7 d,
pregnant women, or those with severe malaria [25] or danger
signs (e.g. prostrate, repeated vomiting, dehydrated) were
excluded. A pregnancy test (Human Chorionic Gonadotro-
phin Combo; Abbotts, Johannesburg, South Africa) was used
to exclude pregnancy in any woman unsure of her pregnancy
status.
Eligible subjects received the six-dose AL treatment
according to body weight, and this was co-administered with
250 ml ‘‘amahewu’’ (a non-alcoholic fermented gruel-like
drink made from maize and containing 0.3 g fat/100 g). The
ﬁrst, third, and ﬁfth doses were administered under obser-
vation at the clinic. Patients were observed for 1 h following
treatment and then allowed to return home. If vomiting
occurred within 30 min of treatment, the patient was re-
treated with a full dose. Vomiting between 30 and 60 min
after treatment resulted in re-treatment with half the dose.
Patients were advised to take the second, fourth, and sixth
doses at home. Self-reported adherence with home treatment
and timing of administration were recorded, together with
pill counts, at each subsequent clinic visit. Concomitant
medication without known antimalarial activity was admin-
Figure 2. Map of Umkhanyakude District, Northern KwaZulu–Natal, South Africa
The map indicates the following: the malaria risk by section and the four sentinel facilities for malaria morbidity and mortality review (Ndumo clinic, and
Mosvold, Manguzi, and Bethesda rural district hospitals); the communities selected for the household (HH) survey and FGDs; and the Manguzi district
hospital where sentinel safety surveillance and Ndumo Clinic where the SP (2000) and AL (2002) in vivo therapeutic efficacy studies were conducted.
DOI: 10.1371/journal.pmed.0020330.g002
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Effect of AL and IRS on Malaria Burdenistered at the investigator’s discretion to relieve malaria
symptoms or treat concurrent disease.
Clinical and parasitological response to treatment, and
occurrence of adverse events were monitored on days 0, 1, 2,
3, 7, 14, 21, 28, and 42 according to modiﬁed World Health
Organization (WHO) procedures [26]. Parasite clearance time
was deﬁned as the interval between initiation of treatment
and the ﬁrst of two consecutive negative thick blood smears.
Filter-paper blood spots were collected for polymerase chain
reaction (PCR) differentiation of re-infection from recru-
descence using nested PCR ampliﬁcations of blocks within
the polymorphic genes encoding glutamate-rich protein and
merozoite surface proteins I and II [27]. Results were
compared with those from a preceding open-label in vivo
study of the therapeutic efﬁcacy of a single dose of SP
monotherapy (at a dose of 1.25 mg/kg pyrimethamine;
Fansidar; Roche, Isando, South Africa), which followed a
similar protocol and was conducted at the same site in 2000
with 98 patients completing 42-day follow-up [5].
Subjects were withdrawn from the study if they developed
any danger signs of severe malaria [25], parasitological
failure, a serious adverse event requiring withdrawal, or if
the patient or their guardian requested withdrawal. ‘‘Rescue
therapy’’ with quinine (quinine sulfate; Lennon Limited,
Port Elizabeth, South Africa) was administered at a dose of
10 mg/kg three times daily for 7 d to patients with
parasitological or clinical failure.
Sentinel Pharmacovigilance
Intensive active sentinel surveillance for serious adverse
events associated with antimalarial drug treatment was
conducted at Manguzi hospital during and immediately
after the malaria season (March–June 2002). This hospital
was selected because it was the rural district hospital in the
high-risk malaria transmission area with adequate resources
to support intensive monitoring. The surveillance pro-
gramme included any person presenting to Manguzi district
hospital with a suspected serious adverse reaction after
being treated with AL, or who was admitted for malaria, or
had been treated for malaria in the 4 wk prior to hospital
presentation. A standardised questionnaire was used to
collect details of symptoms, clinical signs, and the results of
special investigations for each patient. An international
multidisciplinary panel, consisting of experienced clinical,
laboratory, and public-health specialists (listed under
acknowledgements), then reviewed the details of each case
with any adverse effect to identify possible causal associa-
tion with AL therapy. The total number of treatment
courses distributed in the study area (Manguzi subdistrict)
was used as a denominator for calculating the rates of
adverse events.
In addition, all adverse events that occurred during the 42
d of follow-up in the in vivo therapeutic efﬁcacy study were
assessed to determine whether AL was a possible or probable
cause according to guidelines of the International Committee
for Harmonisation and the Medicines Control Council, the
South African Drug Regulatory Authority [28,29]. These
guidelines differ, in that lack of efﬁcacy is classiﬁed as an
adverse drug reaction in the Medicines Control Council
guidelines, but not in the International Committee for
Harmonisation guidelines.
Household Surveys
Care-seeking behaviour for fever and malaria, and patient
adherence with prescribed antimalarial treatment, were
assessed using a survey questionnaire administered in the
local language, isiZulu, to household members by speciﬁcally
trained ﬁeld teams between 6 to 12 wk after the implementa-
tion of AL. The highest risk communities within KwaZulu–
Natal, with malaria notiﬁcation rates ranging from 250 to 800
cases of malaria per 1,000 population in 1998–1999, were
identiﬁed using the Malaria Control Programme Geographic
Malaria Information System platform [21]. However, Muzi 2
section could not be accessed because of severe ﬂoods, and
was replaced by Ngutshana 6, the section with the next
highest malaria notiﬁcation rates recorded in 2000–2001. All
439 households in the seven selected malaria sections were
included in the survey (Figure 2).
Care-seeking behaviour was explored for three groups of
respondents: those who reported being diagnosed with
malaria in the previous 4 wk, those who reported an episode
of fever (not considered by the respondent to be malaria) in
the previous 4 wk, and those who reported ‘‘ever having had’’
malaria. Malaria diagnosis is generally deﬁnitively conﬁrmed
in patients seeking care at formal health-care facilities (rapid
diagnostic testing is provided free of charge to both public-
and private-sector facilities by the malaria control pro-
gramme), but would be diagnosed clinically in those seeking
treatment from traditional healers or not seeking treatment
outside the home.
Patient adherence to antimalarial treatment was assessed
by asking three main questions deliberately interspersed
between other interview topics: (1) Do you have any
treatment for malaria at home? (2) Do you still have any of
this treatment (from this most recent malaria episode)
remaining? and (3) Did you complete the malaria treatment
course for your most recent infection?
Focus Group Discussions
Four focus group discussions (FGDs) were conducted with
8–16 female household heads or caregivers in each of the
areas selected for the household survey, to facilitate a greater
understanding of community perspectives on treatment
seeking and adherence to malaria treatment. The FGDs were
conducted by an independent isiZulu–speaking qualitative
researcher, in the home of a volunteering participant.
Discussion topics included distinguishing between fever and
malaria, management of children and adults with fever or
suspected malaria, and factors inﬂuencing adherence with
medication.
Analysis
Data were double entered, veriﬁed, and, for the household
survey, analysed using Microsoft Access 2000 (Microsoft,
Redmond, Washington, United States). EpiInfo 3.01 (Centers
for Disease Control, Atlanta, Georgia, United States) was used
for analysing sentinel hospital and safety surveillance data.
SPSS Version 8.0 (SPSS, Chicago, Illinois, United States) was
used for analysing the in vivo study. Normally distributed
continuous variables were compared using the t-test for
independent samples, and proportions were compared using
chi square tests (Yates’ corrected or Fisher’s exact, where
appropriate), or odds ratios.
Stata 8.0 (College Station, Texas, United States) was used to
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measure, the area under the gametocyte time curve (AUC),
was calculated using the linear trapezoidal rule. Gametocyte
density was compared between groups using the ratio of
arithmetic means. This was done by ﬁtting generalized linear
mixture models with a logarithmic link function to model the
logarithm of the (arithmetic) mean gametocyte density and a
logistic link function to model gametocyte prevalence using a
zero-inﬂated negative binomial distribution. This accounted
for the typically skewed distributions and excess variance, and
allowed inclusion of all data points (including zeroes),
modiﬁed from the method of Sutherland et al. [11]. This
model generated parallel results that provided estimates of
the relative risk of a zero gametocyte density and estimates of
the incidence rate ratio of the mean gametocyte densities in
the two treatment groups [30].
FGDs were independently analysed by two authors (KIB
and SSD) who identiﬁed consistent themes or analytical
categories in the data using an iterative approach, based on
an adaptation of the grounded theory approach [31]. FGD
ﬁndings were conﬁrmed by a third independent reviewer.
The ﬁndings of the household survey and FGDs were
compared for consistency, thus reducing the possibility of
systematic distortions inherent in using only one method [32].
Ethical Considerations
This study was approved by the Research Ethics Commit-
tees of the University of Cape Town and the South African
Medical Research Council, and was planned and conducted in
full partnership with the KwaZulu–Natal Ministry of Health.
In the in vivo studies, written informed consent was obtained
in the patients’ local language, isiZulu, from all literate
patients or guardians, and an independent literate witness
conﬁrmed verbal consent for illiterate patients or guardians
who also recorded their consent as an ‘‘X’’ on the consent
form. Verbal informed consent was obtained from partic-
ipants in the household survey and FGDs. Conﬁdentiality of
patient identity was maintained for all records.
Results
Review of Malaria Cases and Deaths
The catchment areas of the three sentinel hospitals studied
include almost 285,000 (47%) of the estimated 600,000
persons at risk of malaria in KwaZulu–Natal in 2000; these
facilities carry the heaviest malaria burden because they are
in the highest risk area in the far northeast of the province.
There was a very marked reduction in the number of malaria
cases, hospital admissions, and deaths in all these sentinel
health-care facilities between 2000 and 2001, that were
sustained (Table 1). Between 2000 and 2001 the number of
malaria deaths and admissions both decreased by 89%, and
malaria outpatient cases decreased by 85%. These initial
reductions in malaria cases (96% versus 86%), admissions
(92% versus 82%). and deaths (93% versus 78%) were
greatest at Mosvold hospital and lowest at Manguzi hospital.
Because Manguzi hospital borders on southern Mozambique,
the migrant proportion of their patients may not have
beneﬁted to the same extent from the change in the ﬁrst-line
treatment policy in KwaZulu–Natal. The KwaZulu–Natal
Department of Health estimates that Manguzi hospital serves
a catchment population of approximately 20,000 people from
southern Mozambique.
The marked reduction in malaria morbidity and mortality
continued at all sentinel facilities. By 2003 the number of
malaria-related outpatient cases and admissions had de-
creased by 99%, and malaria-related deaths had decreased by
97%. Trend analysis showed a highly signiﬁcant decrease at
all sentinel hospitals (p , 0.001).
Table 1. Confirmed Malaria Cases and Malaria-Related Hospital Admissions and Deaths in the Sentinel Health-Care Facilities with the
Highest Incidence of Malaria in Northern KwaZulu–Natal, South Africa, between 2000 and 2003
Cases Year Ndumo Clinic
(111,223)
a
Mosvold Hospital
(94,024)
a
Manguzi Hospital and Clinics
(72,811)
a
Bethesda Hospital
(278,058)
a
Total
Confirmed P. falciparum
outpatient cases
b
2000 30,885 (1.0) 6,217 (1.0) 26,308 (1.0) 2,218 (1.0) 65,628 (1.0)
2001 3,635 (0.12) 246 (0.04) 5,223 (0.14) 168 (0.07) 9,572 (0.15)
2002 733 (0.02) 152 (0.02) 287 (0.01) 66 (0.03) 1,238 (0.02)
2003 198 (0.01) 39 (0.01) 214 (0.01) 16 (0.01) 467 (0.01)
v
2 for trend NA p , 0.001 p , 0.001 p , 0.001 p , 0.001
Malaria-related admissions
b 2000 5,465 (1.0) 1,832 (1.0) 1,309 (1.0) 8,606 (1.0)
2001 434 (0.08) 342 (0.18) 129 (0.10) 905 (0.11)
2002 133 (0.02) 108 (0.06) 36 (0.03) 277 (0.03)
2003 39 (0.01) 63 (0.03) 22 (0.02) 124 (0.01)
v
2 for trend p , 0.001 p , 0.001 p , 0.001 p , 0.001
Malaria-related deaths
b 2000 107 (1.00) 40 (1.00) 115 (1.00) 262 (1.00)
2001 8 (0.07) 9 (0.22) 13 (0.11) 30 (0.11)
2002 8 (0.07) 2 (0.05) 6 (0.05) 16 (0.06)
2003 3 (0.03) 3 (0.07) 1 (0.01) 7 (0.03)
v
2 for trend p , 0.001 p , 0.001 p , 0.001 p , 0.001
aThe catchment population of each health-care facility.
bThe population at risk is based on 2001 national census data, and the RR (in parentheses) is compared with 2000 (before AL deployment and the year improved vector control was introduced).
NA, denominator of Ndumo catchment population not reliably available.
DOI: 10.1371/journal.pmed.0020330.t001
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Between January and June 2002, 100 patients (53 female)
with uncomplicated malaria who sequentially met inclusion
criteria were enrolled in this study. Patients had a median age
of 14 y (interquartile range [IQR] 9–28 y) with 5% under 5 y
of age. The geometric mean parasite density at baseline was
26,705/ll (95% conﬁdence interval [CI]: 20,385 to 34,985). The
median duration of symptoms at presentation was 3 d (range
0–14 d). Paracetamol (approximately 15 mg/kg) was adminis-
tered at least once to 87% of patients. Antibiotics (without
antimalarial activity) were administered to three patients in
addition to AL. Two patients were lost to follow-up on day 28,
and one patient missed his follow-up visit on day 28 but
attended the day 42 visit. Parasites reappeared in one patient
on day 28. Because the PCR results for this patient were
indeterminate, this was assumed conservatively to be a
recrudescence. There were no other parasitological failures
and no clinical treatment failures. Of the 100 patients, two
carried gametocytes after treatment; both these patients had
gametocytes present in their blood smears at enrolment. No
gametocytes developed in any patient in whom gametocytes
were absent on day 0.
These results were compared with the in vivo study of the
therapeutic efﬁcacy of SP conducted in 2000 at the same
sentinel study clinic, in a study population with a median age
of 13 y (IQR 7–18 y) with 17% under 5 y of age.[6] The
baseline geometric mean parasite density was signiﬁcantly
higher in the SP monotherapy study (62,114/ll [95% CI:
47,570–81,104]); p , 0.05. Pretreatment gametocyte carriage
was 1/98 in 2000 and 3/100 in 2002 (p ¼ 0.621). Parasite
clearance time was signiﬁcantly more rapid after AL (54 h [CI:
47–60]) than after SP (125 h [CI: 70–180]). Parasitological cure
rates at 42 d of follow-up (corrected for PCR-conﬁrmed
reinfections) was 11/98 (11%) with SP monotherapy com-
pared with 97/98 (99%) with AL in the present study (p ,
0.001). Survival analysis conﬁrmed markedly superior clinical
and parasitological responses following AL, when compared
with SP (log-rank test p , 0.001) (Figure 3). Early treatment
failures decreased from 15/98 (15%) with SP to 0/98 with AL
(p , 0.001) and late parasitological failures decreased from
72/98 (73%) to 1/98 (1%) (p , 0.001). Reinfections during
follow-up decreased from 4/98 in 2000 to 0/98 in 2002 (p ¼
0.121).
During the 2000 SP in vivo therapeutic efﬁcacy study, 52
(57%) of the 91 study subjects for whom gametocyte densities
were recorded were found to carry gametocytes after treat-
Figure 3. Kaplan-Meier Survival Analysis of Time to Clinical or
Parasitological Failure
Following treatment with SP in 2000 (n ¼ 98) and artemether-
lumefantrine in 2001 (n ¼ 100), the proportion of patients with an
adequate clinical and parasitological response to treatment at each day
of follow up is shown.
DOI: 10.1371/journal.pmed.0020330.g003
Figure 4. Scatter Plot of Individual Patient Gametocyte Densities
The gametocyte densities (per microlitre) are given over time following treatment with SP (2000) and AL (2002).
DOI: 10.1371/journal.pmed.0020330.g004
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(relative risk [RR]: 28.5 [95% CI: 7.16 to 113.97]); p , 0.001]
(Figure 4). Gametocyte carriage peaked on day 7 following SP
treatment, and on day 0 (prior to starting treatment) for AL.
The median gametocyte area under the time curve (AUC)
decreased signiﬁcantly from 420 (IQR: 0–2,797) gametocytes/
ll per person-week after SP to 0 (IQR: 0–0) gametocytes/ll
per person-week after AL (Kruskal-Wallis p , 0.001).
Regression analysis of the cumulative area under the
gametocyte time curve found that the RR of a zero
gametocyte density following treatment was 44-fold higher
(95% CI: 13–148) after AL than SP, representing a 97.7%
relative reduction in gametocyte prevalence (p , 0.001). In
addition, AL was associated with a 95% decrease in
gametocyte density among those carrying gametocytes
(incidence rate ratio¼0.050; 95% CI: 0.009–0.274; p¼0.001).
Safety Monitoring and Adverse Events
Of 17 adverse events reported by patients recruited into
the in vivo study, four were considered probably related to
AL, but none of these was considered serious. A case of
urticaria on day 1 resolved with administration of an
antihistamine (without discontinuation of AL). There were
two cases of vomiting and one possible treatment failure on
day 28. Four patients demonstrated a sustained decrease in
haemoglobin (Hb), although this was considered of potential
clinical signiﬁcance in only one case (Hb¼93 g/l on day 0, Hb
¼ 70 g/l on day 7, and Hb ¼ 74 g/l on day 42). The Hb level
remained above 100 g/l, despite a decrease of at least 20 g/l, in
the other three patients. Mouth ulcers that affected three
patients after AL, and pre-existing vomiting that persisted in
two cases after AL, were considered possibly related to
treatment. The remaining adverse events were considered
more likely due to malaria (body pains, n¼2) or inter-current
illness (chest pain which resolved with amoxicillin, n ¼ 1; ear
infection, n ¼ 1).
From April to June 2002, when approximately 310 blister
packs of 24 tablets were dispensed in this hospital’s catch-
ment area, a total of 44 patients admitted to Manguzi hospital
met the inclusion criteria of the intensive hospital-based
safety monitoring study. Two of these patients did not
provide consent and were thus excluded from the study.
The remaining 42 patients, of whom 12 (29%) were under 2
years of age, were admitted either for malaria (n ¼36), or for
persistent (n ¼ 5) or new (n ¼ 1) symptoms following
antimalarial treatment.
A total of 13 patients were treated with AL before (n¼5) or
during (n ¼ 8) their hospital stay. The ﬁve patients who had
recently been treated with AL were admitted because of a
poor response to AL, although it was not conﬁrmed whether
or not these patients had adhered fully to this treatment.
These would not be considered adverse drug reactions
according to International Committee for Harmonisation
criteria. One 14-y-old female patient died. She had appa-
rently received AL 3–4 d prior to her death, and was then
treated with an unidentiﬁed herbal mixture by a traditional
healer when she did not improve. She was admitted with a
diagnosis of possible cerebral malaria with herbal intoxica-
tion and died within 24 h of admission. On admission her
malaria smear was negative and a cerebrospinal ﬂuid
examination conﬁrmed bacterial meningitis; the multidisci-
plinary expert review team concluded that her death was
unlikely to be related to AL. One 24-y-old female patient
treated during hospital stay with AL and doxycycline
experienced vomiting after receiving the ﬁrst and subsequent
dose; this was considered a possible adverse reaction to AL
and/or doxycycline.
Community Perspectives on Malaria Treatment Seeking
and Adherence
Two of the 439 households selected for the household
survey elected not to participate, and one respondent was
unable to complete the interview due to illness (data from the
portion of her interview completed was included in this
analysis). Data were collected on a total of 2,506 household
members of whom 55% were female. The average estimated
distance from study households to the nearest public health-
care facility was 6.5 km, and this took an average of 90 min to
reach. Overall 68% of household members had previously
suffered from malaria.
Respondents reported that 239 (10%) household members
had suffered from malaria in the 4 wk immediately preceding
the household survey, which was conducted during February
and March 2001 at the peak of the malaria transmission
season, and 4 to 6 wk after the implementation of AL. Of
these, only four (1.7%) reported not seeking treatment
outside the home. Most had ﬁrst sought treatment at either
a Malaria Control Programme ﬁeld camp (n ¼101; 42%) or a
public sector clinic (n ¼ 127; 53%). Five patients reported
initially seeking treatment at a public hospital, whereas one
patient sought treatment from a private doctor, and one
indicated ﬁrst going to a traditional healer. Respondents
reported that 226 (96%) had completed recent treatment (i.e.,
taken all prescribed tablets) but were uncertain whether a
further seven (3%) household members had completed
treatment. These responses were consistent with those
regarding whether there was any antimalarial treatment
remaining at home, with only two patients (1%) admitting
that they still had antimalarial tablets (both AL) remaining
from the recent treatment course.
Amongst household members that reported never having
had malaria (‘‘malaleveva’’), 26% (204/785) reported experi-
encing fever (‘‘umkhuhlane’’) in the 4 wk prior to the
household survey. Only 88 (43%) had sought care outside
the home. Of those seeking fever treatment, 79 (90%) had
presented to a public sector clinic, ﬁve at a public sector
hospital, one to a private doctor, two to a Malaria Control
Programme ﬁeld camp, and one to a traditional healer. A
signiﬁcantly greater proportion of patients with recent
perceived malaria (235/239; 98%) than those with a recent
febrile disease not considered to be malaria (88/204; 43%)
sought treatment at health-care facilities (RR: 2.28; CI: 1.95–
2.67; p , 0.001).
Participants in all four FGDs agreed that if home treatment
was not successful in rapidly alleviating malaria symptoms,
the affected household member would be taken to the nearest
public health-care facility. The FGDs revealed that people
generally ﬁrst attempted treatment of ‘‘just’’ fever with herbal
medicines and enemas. Participants mentioned weakness and
headache more often than fever as a feature they associate
with malaria; participants commented that malaria, unlike
‘‘just’’ fever, was not self limiting. When asked about sources
of treatment for malaria fever, all FGDs emphasized that
there was no effective alternative to public health-care
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urgently: ‘‘There’s nothing else, you rush to the clinic’’ and
‘‘I have never heard of someone who cleared malaria at home,
without going to the clinic.’’ Delaying treatment seeking was
considered potentially fatal: ‘‘Once you don’t go to the clinic,
it kills.... You will die from malaria’’ and ‘‘Once you waste
time at the sangoma [traditional healer], you die.’’
The change in treatment policy from SP to AL appeared
well accepted, because SP was regarded as ineffective: ‘‘These
tablets (SP) which were used before the present ones [AL]—
most of us didn’t like taking them....You would feel as if the
malaria has become more severe,’’ ‘‘Every year I used to have
malaria. This year I heard that new pills were coming. I was
very sick with malaria. They gave me the [new] pills.... The
[next] morning I was very ﬁne.... I have cultivated and
harvested and I’ve never had malaria [again] this year.’’
Although FGD participants generally reported completing
full malaria treatment courses (‘‘We ﬁnish the malaria
treatment because we have seen that it [malaria] ﬁnishes
[kills] us’’), a few individuals indicated terminating treatment
once symptoms resolved and saving remaining medication
for future use.
Discussion
Reversing the alarming increase in malaria associated
mortality in Africa is possible with use of existing effective
methods of vector control and widespread use of highly
effective ACT. KwaZulu–Natal Province was experiencing an
epidemic of malaria fuelled by re-emergence of an insecti-
cide-resistant mosquito vector and spiralling resistance to SP.
There was a dramatic response to strengthening the vector
control programme and wide-scale implementation of an
ACT, AL, in this low-intensity malaria transmission setting;
the number of malaria cases fell by 99%. The implementation
of these dual interventions in KwaZulu–Natal was found to be
cost effective and resulted in substantial cost savings [33].
Malaria transmission is multifactorial: In KwaZulu–Natal,
where malaria control operations are intense, exploration of
monthly malaria case data between 1971 and 2001 found that
climatic factors only inﬂuenced interannual variation in
malaria transmission but not the medium to long term trends
in case totals, which were signiﬁcantly associated only with
antimalarial resistance and HIV prevalence [34,35]. Despite
the continued increase in antenatal HIV seroprevalence in
KwaZulu–Natal from 32.5% in 1999 to 40.7% in 2004 (http://
www.doh.gov.za/aids/index), we observed a 99% reduction in
conﬁrmed malaria cases. However, HIV coinfection may have
precluded a greater reduction in malaria-related admissions
and deaths because this coinfection has been shown to
increase the risk of severe malaria and malaria-related deaths
in the non-immune KwaZulu–Natal population [36]. There
were no other substantial social, political, and health-care
changes likely to affect malaria burden during the study
period, although small effects cannot be excluded.
Notiﬁcation of communicable diseases is constrained by
under-reporting and this is particularly severe during
epidemics in resource poor areas, when health workers
probably prioritise patient management over notiﬁcation
[37]. The increased demand placed on health-care providers
by the large-scale malaria epidemic in KwaZulu–Natal
Province that peaked in 2000 suggests that under-notiﬁcation
may have been particularly prevalent during that year. It is
expected that any delay in changing the SP malaria treatment
policy and in strengthening vector control would have
resulted in increased malaria transmission and further
increases in malaria morbidity and mortality. Thus the
remarkable reduction in malaria case notiﬁcation docu-
mented here is probably an underestimate of the true effect
of implementing effective treatment and improving vector
control.
The decreases in malaria morbidity and mortality observed
in KwaZulu–Natal Province reﬂect both the therapeutic
effects of AL and the enhanced malaria vector control
(following the reintroduction of DDT and extension of IRS to
neighbouring southern Mozambique). The reliable and rapid
therapeutic response to ACTs, combined with their effect of
reducing gametocyte carriage, make them ideal treatments.
The dramatic reductions in gametocyte prevalence and
density observed would substantially contribute to reducing
malaria transmission [11]. The relative contributions of the
two strategies, deliberately introduced in short succession to
optimise public health impact, cannot be accurately appor-
tioned. The extent of the public health impact observed
following the policy change to ACTs is unlikely to have been
achieved in the absence of effective vector control. Equally,
we believe that the beneﬁts of reintroducing DDT for IRS of
traditional (but not western-style) structures would have had
less beneﬁt without the replacement of highly ineffective SP
with an effective acceptable ACT, given the 89% treatment
failures and high gametocyte carriage rates observed follow-
ing SP monotherapy.
On the northwestern border area of Thailand, a 47%
reduction in the incidence of P. falciparum infections was
observed in the 12 mo following the introduction of
artesunate plus meﬂoquine, when no changes were made to
vector control [38]. This improved further to a 6-fold
reduction over a 10-y period of use [7]. The similar
experience of marked public health beneﬁts in northwestern
Thailand suggests that the results in KwaZulu–Natal Province
reﬂect the beneﬁts of effective ACT, rather than being
speciﬁc to AL. The area studied on the western border of
Thailand is similar to KwaZulu–Natal in terms of a low
intensity of seasonal malaria transmission (annual entomo-
logic inoculation rate , 1) and reasonably high levels of
access to health-care facilities providing deﬁnitive diagnosis
of malaria and relatively reliable, well-regulated drug supply.
The reduction in malaria mortality by ACTs reﬂects both the
reduced incidence of malaria following decreased gametocyte
carriage, and the reliable and rapid antimalarial activity of
the ACT. General deployment of artemisinin in Vietnam was
also associated with a marked and sustained reduction of
malaria mortality [39].
The improvement in clinical and parasitological cure rate
from 11% to 99% is particularly important in KwaZulu–
Natal, because the low intensity of malaria transmission and,
consequently, the low levels of acquired immunity mean that
a substantial proportion of patients with parasitological
failure would develop recrudescent P. falciparum infections
or even progress to severe malaria. The high AL cure rate,
similar to the 97%–98% published recently in large rando-
mised controlled trials reported from East Africa [40,41], was
achieved despite co-adminstration at the clinic with a
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its widespread availability. Previous studies have shown that
lumefantrine absorption is highly dependent on coadminis-
tration with fat, although the minimum fat content required
for adequate absorption has not yet been deﬁned [42].
Similarly to previous studies [43,44], we documented that
AL was well tolerated both in the sentinel surveillance
programme at Manguzi hospital, and in patients enrolled in
the in vivo study who were closely monitored. This probably
contributed to the generally good adherence reported.
However, the markedly decreased malaria incidence in
KwaZulu–Natal Province limited our ability to detect
uncommon serious adverse effects of AL.
In South Africa, orthodox medicines are relatively strictly
regulated, and AL treatment requires prescription by a
registered health-care provider. ACT coverage depends on
treatment seeking at health-care facilities where AL is
available. Household survey results demonstrated that the
majority (97%) of people with recent symptoms thought to
result from malaria initially sought treatment at public
health-care facilities. For recent fevers not considered by
respondents to be related to malaria, however, seeking
treatment outside the home was signiﬁcantly less frequent,
although the public clinics remained the most popular source
of health care. These malaria-speciﬁc treatment-seeking
patterns are likely to have been enforced by the regular
communication between the provincial Malaria Control
Programme and the community. The general preference for
public health-care facilities may be associated with the
provision of free health care for notiﬁable diseases in public
sector clinics and a relatively high level of access to these
facilities, with 81% of the population living within 10 km of
a public clinic in northern KwaZulu–Natal [21]. This pattern
of treatment-seeking behaviour was conﬁrmed during the
FGDs, in which fear of malaria and perceived effectiveness
of treatment served as key factors motivating patients to
seek treatment from public health-care facilities. High levels
of AL coverage are thus achievable in northern KwaZulu–
Natal through public-sector implementation alone, provided
that patients recognise malaria symptoms. Because ACT
coverage is considered an important determinant of
community beneﬁt in terms of reducing malaria trans-
mission and slowing antimalarial resistance, ensuring ready
access to this treatment (and deﬁnitive diagnosis) is a key
component of effective malaria control. This cannot be
achieved without addressing local health-care infrastructure
needs and ensuring a high level of health literacy in the local
community.
Adherence with prescribed antimalarial treatment regi-
mens is essential to optimise cure rates and prevent
resistance. There were some inconsistencies between house-
hold survey and FGD ﬁndings on patient adherence, with a
few FGD participants indicating that they would stop
treatment once symptoms resolved and save medication
for future episodes. These FGD ﬁndings conﬁrm, but cannot
quantify, the general trend that self-reporting tends to
overestimate levels of adherence, because patients who
report poor adherence are generally accurate, whereas those
who deny poor adherence may not be [45]. Although the
consistently high levels of adherence reported in the answers
to three different questions, and the dramatic reductions in
malaria morbidity and mortality are reassuring ﬁndings, it
has been suggested that the public health consequences of
partial adherence are delayed until cure rates start to
decline [46]. There is a clear need for better measures of
adherence in general and, for AL in particular, for ongoing
efforts by health staff to encourage patients to complete all
six doses and to co-administer it with a fat-containing drink.
There are a number of factors to be considered before
assuming direct generalisability of our ﬁndings to other
countries, including: whether the current malaria treatment
policy is already highly effective, whether baseline resistance
to the non-artemisinin component of the ACT is higher,
whether home treatment and treatment seeking in the
informal or private sector is more prevalent, whether
malaria diagnosis is clinical or conﬁrmed, and perhaps most
importantly, the intensity of malaria transmission intensity.
Recent data suggest fewer than half of the populations at
risk of malaria globally live in areas of high-intensity malaria
transmission, with 25.4% of those at risk living in low-
intensity transmission areas and a further 31.3% living in
areas of moderate-intensity malaria transmission [47].
Decreasing malaria morbidity and mortality substantially
in high-transmission areas, as in much of sub-Saharan
Africa, is expected to be considerably more challenging.
The higher risk of new malaria infections could impact on
the overall effectiveness of ACTs, and ACT coverage and
compliance may be lower in semi-immune individuals
because a substantial proportion of infections would be
asymptomatic and symptoms would more likely resolve with
incomplete treatment. There are fewer examples of success-
ful large-scale vector control programmes in high-intensity
transmission areas.
Between the 1940s and 1960s, pilot malaria eradication
projects across sub-Saharan Africa recorded signiﬁcant
reductions in malaria [48]. Subsequently, systematic indoor
residual insecticide spraying programmes have been highly
successful in reducing malaria transmission, particularly in
southern Africa and island states [49]. Similarly, widespread
coverage with insecticide-treated bed nets in areas of high-
intensity malaria transmission has resulted in sustained
protection of both individuals and communities against
malaria [50]. These ﬁndings suggest that effective sustainable
vector control may be achievable across all levels of malaria
endemicity and could limit the number of malaria cases
requiring ACT treatment, particularly if malaria is deﬁni-
tively diagnosed. This would increase the affordability of
ACTs and adequacy of ACT supply, and be expected to
optimise the effect of ACTs on malaria transmission.
Conclusions
We consider the ready access to treatment in a relatively
well-developed rural primary health-care infrastructure,
coupled with an effective vector control programme,
important factors for deriving the greatest beneﬁt from
ACT implementation. Equally important are the strong
community perceptions that malaria diagnosis and treat-
ment should be sought urgently at public health-care
facilities and treatment then completed. These factors
deserve consideration by those responsible for reducing
malaria morbidity and mortality, because wide-scale imple-
mentation and rational use of effective vector control and
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Patient Summary
Background Malaria is caused by a parasite transmitted by some types
of mosquito; it kills about a million people every year, especially children
in Africa. The disease has become more common in recent years because
the parasites have become resistant to many malaria drugs and the
mosquitoes have developed resistance to insecticides. Between 1995
and 2000, malaria increased dramatically in South Africa’s KwaZulu–Natal
province. The main reasons for the increase are believed to be resistance
to the drug sulfadoxine-pyrimethamine (SP) and to pyrethroid types of
insecticide. In 2000, in response, a new drug called artemether-
lumefantrine (AL) was introduced to treat people with malaria. (AL is a
combination drug that includes artemisinin, which has been shown to
work in control programs in Asia, but this the first time a drug of this
type has been used in a program in Africa.) Mosquito control efforts were
also increased and, although pyrethroids were still used in some
situations, the older insecticide DDT was also reintroduced.
What Did the Researchers Do and Find? They measured the success of
the action taken in KwaZulu–Natal. In the year following the changes,
hospital admissions for malaria declined by 89% and so did deaths;
outpatient cases decreased by 85%. By 2003, outpatient cases and
admissions had both fallen by 99% and deaths had decreased by 97%.
AL treatment cured 99% of cases, compared with the 11% cure rate
previously found with SP. Most patients (96%) said they completed the
six-dose course of AL, and no serious drug side effects were reported.
What Does This Mean? The study shows an encouraging and important
example of how malaria can be effectively fought. Because both better
mosquito control and better drugs were introduced around the same
time, the researchers could not say how much each of the two measures
contributed to the overall success. However, it is likely that both
contributed, and it shows that the two together can be very effective.
When applying the lessons from this success story to other parts of Africa
and to other continents, one needs to keep in mind that the starting
conditions in KwaZulu–Natal were quite favorable. For example, there is
a low level of background immunity against malaria, which means that
infected people usually get quite sick and seek treatment rather than
acting as reservoirs for further transmission. In addition, most patients
can get prompt diagnosis and treatment because the province has a
reasonable health-care infrastructure.
Where Can I Get More Information? The Roll Back Malaria Department
of the World Health Organization has a Web site with information about
the disease and the global efforts to fight it (this site also has links to
other organizations and to useful publications):
http://www.who.int/malaria
The South African Department of Health Web site includes guidelines on
the treatment of malaria (2002) and prevention of malaria (2003):
http://www.doh.gov.za/docs/index.html
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